BioInvent International AB: Interim Report January-March 2024

2024-04-24

临床1期临床结果财报免疫疗法引进/卖出

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs." - Martin Welschof, CEO of BioInvent. EVENTS IN THE FIRST QUARTER (R) CASI Pharmaceuticals reported positive interim Phase 1 data for BI-1206 in NHL in China Supply agreement signed with AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence® (acalabrutinib) BioInvent regained the rights to immuno-oncology targets from Exelixis EVENTS AFTER THE END OF THE PERIOD New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab) (R)= Regulatory event FINANCIAL INFORMATION First quarter 2024 Net sales, SEK 5.9 (16.2) million Profit/loss after tax, SEK -77.9 (-73.7) million Profit/loss after tax per share before and after dilution, SEK -1.18 (-1.12) Cash flow from operating activities, SEK -65.9 (-78.9) million Liquid funds, current and long-term investments at the end of the period, SEK 1,219.2 (1,546.4) million The complete interim report is available for download below and on the company's website . About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at . Follow on Twitter: @BioInvent. Attachments BioInvent Q1, 2024 EN Final SOURCE: BioInvent International View the original press release on accesswire.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构